These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23190063)

  • 1. New treatments on the horizon for familial hypercholesterolemia.
    Allian-Sauer MU; Falko JM
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1227-37. PubMed ID: 23190063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.
    Mabuchi H; Higashikata T; Kawashiri MA
    Transfus Apher Sci; 2004 Jun; 30(3):233-43. PubMed ID: 15172629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
    Raal FJ; Santos RD
    Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia.
    Streicher J; Valent P; Schmidt H; Sengölge G; Wagner O; Strobl W; Hörl WH; Derfler K
    J Investig Med; 1999 Sep; 47(8):378-87. PubMed ID: 10510590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
    Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
    Lee WP; Datta BN; Ong BB; Rees A; Halcox J
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Chinese homozygote of familial hypercholesterolemia: identification of a novel C263R mutation in the LDL receptor gene.
    Wang D; Wu B; Li Y; Heng W; Zhong H; Mu Y; Wang J
    J Hum Genet; 2001; 46(3):152-4. PubMed ID: 11310584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes.
    Alonso R; Mata P; Zambón D; Mata N; Fuentes-Jiménez F
    Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):327-42. PubMed ID: 23469913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLA Symposium screening and treatment of familial hypercholesterolemia: how can we do better? Opening and introductions.
    McGowan M
    J Clin Lipidol; 2010; 4(5):335-7. PubMed ID: 21122673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
    Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.
    Page MM; Bell DA; Hooper AJ; Watts GF; Burnett JR
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):387-403. PubMed ID: 24840266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.